The resistance of tumors to classic taxanes (paclitaxel and docetaxel) presents problems in chemotherapy. Thus, new taxanes with higher antitumor activity in resistant tumors are synthesized. This study compared cytotoxicity and transport of paclitaxel and docetaxel with novel taxanes SB-T-1103, SB-T-1214, and SB-T-1216 in adriamycin-sensitive (MDA-MB-435) and -resistant (NCI/ADR-RES) human breast cancer cells. The cell lines examined differ in adriamycin transport, suggesting different expression of ABC membrane transporters. Reverse transcription-polymerase chain reaction revealed that NCI/ADR-RES cells expressed high levels of P-glycoprotein mRNA, which was absent in MDA-MB-435 cells, while the opposite was true for MRP2 mRNA. Both cell lines shared or differently expressed eight other ABC transporters and LRP. NCI/ADR-RES cells were 1,000-fold more resistant to paclitaxel and 600-fold more resistant to docetaxel in MTT assay than MDA-MB-435 cells, but almost equally sensitive to SB-T-1103, SB-T-1214, and SB-T-1216. This complied with the fact that NCI/ADR-RES cells absorbed almost 20-fold less [14C]paclitaxel, about 7-fold less docetaxel, and almost equal amounts of SB-T-1103, SB-T-1214, and SB-T-1216 as the MDA-MB-435 cells. Verapamil increased uptake of [14C]paclitaxel by NCI/ADR-RES cells 7-fold and decreased its efflux 2.5-fold; in contrast, it weakly influenced uptake and increased the efflux in MDA-MB-435 cells. SB-T-1103 and SB-T-1216 did not influence transport of paclitaxel, but SB-T-1214 decreased [14C]paclitaxel uptake in both cell lines indicating inhibition of uptake. This suggests that the novel taxanes are not inhibitors of P-glycoprotein. However, novel taxanes exert much higher activity on resistant tumor cells than classic taxanes and seem to be potential drugs for therapy in taxane-resistant tumors.

Cell Growth Control Laboratory Institute of Molecular Genetics Academy of Sciences of the Czech Republic Videnska 1083 142 00 Prague 4 Czech Republic

Zobrazit více v PubMed

J Biol Chem. 2003 Oct 10;278(41):39706-10 PubMed

Clin Cancer Res. 2000 Aug;6(8):3205-14 PubMed

Pflugers Arch. 2001;443 Suppl 1:S22-7 PubMed

Arch Toxicol. 2000 Oct;74(8):437-46 PubMed

Br J Cancer. 2001 Oct 19;85(8):1175-84 PubMed

Biochem Pharmacol. 1998 Sep 15;56(6):719-27 PubMed

Genome Res. 2001 Jul;11(7):1156-66 PubMed

Anticancer Res. 2004 Sep-Oct;24(5A):2931-9 PubMed

J Chromatogr B Biomed Sci Appl. 2000 Oct 10;748(2):383-8 PubMed

Cancer Res. 2004 Jun 15;64(12):4294-301 PubMed

Nat Med. 1995 Jun;1(6):578-82 PubMed

Br J Cancer. 2000 Dec;83(12 ):1762-8 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):200-9 PubMed

Cell Mol Life Sci. 2001 Jun;58(7):931-59 PubMed

J Med Chem. 1996 Sep 27;39(20):3889-96 PubMed

Drugs. 1998 Jan;55(1):5-30 PubMed

J Immunol Methods. 1983 Dec 16;65(1-2):55-63 PubMed

Pharmacol Rev. 1990 Sep;42(3):155-99 PubMed

Int J Cancer. 2005 May 20;115(1):155-63 PubMed

Chem Rec. 2001;1(3):195-211 PubMed

Biochem Pharmacol. 1996 Feb 9;51(3):301-11 PubMed

J Pharmacol Exp Ther. 2001 Oct;299(1):164-70 PubMed

Anal Biochem. 1987 Apr;162(1):156-9 PubMed

Biochim Biophys Acta. 1997 Aug 22;1361(2):169-76 PubMed

Int J Cancer. 2001 Jul 1;93(1):114-22 PubMed

Gynecol Oncol. 2004 Apr;93(1):98-106 PubMed

Mol Membr Biol. 2001 Apr-Jun;18(2):145-52 PubMed

Effect of substituents at the C3´, C3´N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells

Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model

The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes

Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells

Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes

Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells

Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells